Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Effect of Essential Oils as Adjutants on the Treatment of Subjects With Periodontitis: Assessment of Metabolic Variables as Effect Modifiers

30 december 2020 bijgewerkt door: Francisco Mesa, Universidad de Granada

Periodontitis, an infectious disease that affects the tooth-supporting tissues and shows a wide range of clinical, microbiological, and immunological manifestations, is associated with and probably caused by dynamic interaction among infectious agents, host immune responses, hazardous environmental exposure and genetic propensity. Bacteria are necessary for the disease to appear, but are not sufficient and do not account for all cases of periodontitis. According to one survey in the USA, chronic periodontitis affects approximately 46% of the adult population, with an even higher prevalence among the elderly. This prevalence refers to the cohort of young adults according to the WHO, with ages ranging from 35 to 44 years. Forms of periodontitis that appear at younger ages (before the age of 30 years), and that have other characteristics in addition to age, are known as aggressive periodontitis. The prevalence of this disorder ranges from 0.2% in Caucasians to 2.6% in Afro-Americans. The microbiota of the human oral mucosa together with other anatomical locations in the body constitute the human microbiome. The equilibrium between these organisms and the host response plays a fundamental role in human biology, both in health maintenance and in the appearance of disease. Unfavorable alterations in the composition of the microbiota are termed dysbiosis.

Antiseptics and antibiotics such as Chlorhexidine or Metronidazole, are delivered locally as an adjunct to scaling and root planing procedures, in order to eradicate the subgingival microbes, hence creating a healthy subgingival environment. However, the results presented in the literature are inconclusive. There is a need for further clinical trials with strict methodological criteria for allowing a more precise assessment of the efficacy of local antimicrobials in the treatment of chronic periodontitis.

Recently, there has been renewed interest in the application of natural products. Several natural products and herbs have claimed to have better properties and less side effects than chemical agents for irrigation. The use of natural extracts and essential oils as an irrigation agent for ultrasonic instrumentation has shown to promote slight adjunctive effect compared to chlorhexidine or water. In other study, natural extract showed a greater improvement compared to controls in patients with a more severe degree of periodontitis. However, in other studies this pocket reduction and clinical attachment gain were no significant when compared to water. Natural products have also been tested in forms of oral spray, and have shown to be effective against common oral pathogens without significant cytotoxicity in an in vitro study. Thus, it has the potential to prevent the infections and may serve as adjunctive treatment to conventional therapy. They claim to have the same or even more anti-microbial effect and anti-inflammatory effect without adding any chemicals. But still there is no adequate scientific evidence to support this hypothesis.

This study aims to test the effect as an adjutant to therapy of a nutraceutical composed of several plant extracts in patients with periodontitis and different levels of risk for metabolic syndrome. Specifically:

  1. The response of periodontal clinical variables to non-surgical periodontal treatment in patients treated with the extract, compared to controls.
  2. The effect on local inflammatory markers, in patients treated with the extract compared to controls.
  3. The modifier effect of metabolic syndrome-related variables in the treatment outcomes of the patients treated with the extract compared to controls.

Hypothesis:

The application of the plant extract would act as an anti-inflammatory agent, contributing to better treatment outcomes of periodontitis, in terms of clinical and biochemical variables.

Studie Overzicht

Toestand

Beëindigd

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

METHODOLOGY

Study design Randomized, controlled, double-blinded clinical trial.

Study unit/population Subjects with diagnosis of periodontitis according to the joint EFP/AAP 2018 criteria for the case definition of periodontitis.

Inclusion criteria Patients attended in the University of Granada School of Dentistry (Granada, Spain) Signing of a written consent.

Exclusion criteria Age under 18 years, received periodontal treatment in the last year, anti-microbial therapy in the previous 3 months, multiple pregnancy and the presence of neoplastic or severe infectious diseases.

Sampling and randomization It is estimated to explore at least 60 patients, of which 30 will be randomized to each group, accordingly to similar studies on the topic available in the literature. The group allocation will also follow similar studies published previously in the field (7-9, 12, 13). All patients will receive standard periodontal treatment with an ultrasonic new generation device (AIRFLOW® Prophylaxis Master, EMS Dental, Nyon, Switzerland), and the group division will be based on the use of the extract as an adjunct to non-surgical treatment.

Test group: Patients that will receive the application of the extract in form of irrigation solutions in the periodontal pockets during regular periodontal treatment. Patients would continue at home during the follow-up period, taking the essential oils in as a rinse twice per day, and as a spray when regular toothbrush could not be performed.

Control group: Patients that will follow the same protocol, but using regular irrigation and a placebo spray at home.

The researchers that will perform the clinical examinations will be blinded for the group allocation of the participants, since the random allocation and prescription will be performed by a different researcher. Study products and placebo will be provided previously by the company BIONAP.

Study variables

  1. Sociodemographic variables: sex, age, smoking habit (cigs/day), alcohol consumption (g/day).

  2. Periodontal clinical variables:

    Periodontal examination will be performed by a calibrated researcher using PCPUNC15 periodontal probe (Hu-friedy, Chicago, IL, USA) and dental exploration mirror. Six surfaces in each implant will be measured: mesiovestibular, vestibular, distovestibular, distolingual, lingual, mesiolingual. All clinical data will be recorded in a periodontal chart. Clinical data will be gathered at baseline, and at 2 and 6 months of follow-up.

    Bleeding on probing: The percentage of bleeding implants while probing, will the registered following the index of Ainamo and Bay (14).

    Oral hygiene: Oral hygiene will be measured using the Plaque Index proposed by Tonetti (15). The presence of plaque will be registered by visual examination without using a plaque revealing agent.

  3. Metabolic syndrome-related variables:

    • Body weight
    • Body height
    • Body mass index
    • Waist circumference
    • Blood pressure
  4. Biochemical variables:

Samples of saliva, subgingival plaque and gingival crevicular fluid will be obtained at the beginning of the study, at 2 months and at the end of follow-up. A panel of inflammatory cytokines will be assessed.

Blood samples will be obtained at the beginning of the study, at 2 months and at the end of follow-up for the assessment of:

  • Fasting blood glucose
  • Lipid profile (Total cholesterol, Triglycerides, LDL-cholesterol and HDL-cholesterol).

Data management and statistical analysis A database in Excel format will be prepared including all recorded variables. The data will be analyzed by a single researcher. The statistical software SPSS v.21.0 (IBM Inc., Chicago, IL, USA) will be used, performing descriptive statistics (means, standard deviations and percentages) and analytical procedures (95% confidence intervals, Mann-Whitney test, Chi-square, Student's t-test for paired samples, and univariate and multivariate regression analysis). A 5% significance level will be considered for all tests.

ETHICAL CONSIDERATIONS The study will be designed in order to comply with the standards of the las revision of the Helsinki declaration. Approval from the Research Ethics Committee in Human Studies of the University of Granada will be obtained prior to the beginning of the study. Written informed consent will be obtained from all participants in the study. All obtained data will be anonymous and the study will be designed following the CONSORT guidelines for reporting clinical trials (16).

WORK PLAN

The project has been planned to be performed in a period of 2 years:

  1. Study registration, ethical approval, and planning: December 2018 - February 2019.
  2. Study enrollment, allocation, samples and data gathering. Follow-up period: March 2019 - April 2020.
  3. Statistical analysis of all data: June 2020 - September 2020.
  4. Manuscript preparation and publication process: October 2020 - April 2021.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

60

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

  • Spanje
      • Granada, Spanje, 18071
        • University of Granada School of Dentistry

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Patients attended in the University of Granada School of Dentistry (Granada, Spain)
  • Accepting to be enrolled in the study and signing of a written consent.

Exclusion Criteria:

  • Age under 18 years,
  • Received periodontal treatment in the last year,
  • Anti-microbial therapy in the previous 3 months
  • Allergies
  • Multiple pregnancy
  • Presence of neoplastic or severe infectious diseases.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Test Group
Patients that will receive the application of the extract in form of irrigation solutions in the periodontal pockets during regular periodontal treatment. Patients would continue at home during the follow-up period, taking the essential oils in as a rinse twice per day, and as a spray when regular toothbrush could not be performed.
Ander: Plant-based oral rinse
Oral rinse enriched with plant-based essential oils.
Placebo-vergelijker: Control Group
Patients that will follow the same protocol, but using placebo irrigation and a placebo spray at home.
Ander: Placebo oral rinse
Oral rinse with the exact characteristics in terms of colour and odour of the plant-based one, but without the essential oils aimed to test in this study

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Pocket probing depth
Tijdsspanne: Change from Baseline Pocket probing depth at 3 months
Depth of periodontal pockets present in the teeth of each patient in millimeters (mm) using a periodontal probe (PCPUNC-15)
Change from Baseline Pocket probing depth at 3 months
Pocket probing depth
Tijdsspanne: Change from Baseline Pocket probing depth at 6 months
Depth of periodontal pockets present in the teeth of each patient in millimeters (mm) using a periodontal probe (PCPUNC-15)
Change from Baseline Pocket probing depth at 6 months
Gingival recession
Tijdsspanne: Change from Baseline Gingival recession at 3 months
Distance from the gingival margin to the cemento-enamel junction in the teeth of each patient in millimeters (mm) using a periodontal probe (PCPUNC-15)
Change from Baseline Gingival recession at 3 months
Gingival recession
Tijdsspanne: Change from Baseline Gingival recession at 6 months
Distance from the gingival margin to the cemento-enamel junction in the teeth of each patient in millimeters (mm) using a periodontal probe (PCPUNC-15)
Change from Baseline Gingival recession at 6 months
Bleeding on probing
Tijdsspanne: Change from Baseline Bleeding on probing at 3 months
Percentage of teeth (%) that showed bleeding during periodontal examination.
Change from Baseline Bleeding on probing at 3 months
Bleeding on probing
Tijdsspanne: Change from Baseline Bleeding on probing at 6 months
Percentage of teeth (%) that showed bleeding during periodontal examination.
Change from Baseline Bleeding on probing at 6 months
Oral hygiene
Tijdsspanne: Change from Baseline Visual Plaque Index at 3 months
Percentage of teeth surfaces (4 in each tooth) that showed visible plaque during periodontal examination (Visual Plaque Index).
Change from Baseline Visual Plaque Index at 3 months
Oral hygiene
Tijdsspanne: Change from Baseline Visual Plaque Index at 6 months
Percentage of teeth surfaces (4 in each tooth) that showed visible plaque during periodontal examination (Visual Plaque Index).
Change from Baseline Visual Plaque Index at 6 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Body weight
Tijdsspanne: Change from Baseline Body weight at 3 months
Weight of each patient in kilograms (Kg) with a body scale.
Change from Baseline Body weight at 3 months
Body weight
Tijdsspanne: Change from Baseline Body weight at 6 months
Weight of each patient in kilograms (Kg) with a body scale.
Change from Baseline Body weight at 6 months
Body height
Tijdsspanne: Baseline
Height of each patient in centimeters (cm) with a scale.
Baseline
Waist circumference
Tijdsspanne: Change from Baseline Waist circumference at 3 months
Waist abdominal circumference of each patient in centimeters (cm) with a measure tape.
Change from Baseline Waist circumference at 3 months
Waist circumference
Tijdsspanne: Change from Baseline Waist circumference at 6 months
Waist abdominal circumference of each patient in centimeters (cm) with a measure tape.
Change from Baseline Waist circumference at 6 months
Systolic Blood pressure
Tijdsspanne: Change from Baseline Systolic Blood pressure at 3 months
Systolic Blood pressure of each patient in Hg millimeters (Hg mm) measured with a sphygmomanometer.
Change from Baseline Systolic Blood pressure at 3 months
Systolic Blood pressure
Tijdsspanne: Change from Baseline Systolic Blood pressure at 6 months
Systolic Blood pressure of each patient in Hg millimeters (Hg mm) measured with a sphygmomanometer.
Change from Baseline Systolic Blood pressure at 6 months
Diastolic Blood pressure
Tijdsspanne: Change from Baseline Diastolic Blood pressure at 3 months
Diastolic Blood pressure of each patient in Hg millimeters (Hg mm) measured with a sphygmomanometer.
Change from Baseline Diastolic Blood pressure at 3 months
Diastolic Blood pressure
Tijdsspanne: Change from Baseline Diastolic Blood pressure at 6 months
Diastolic Blood pressure of each patient in Hg millimeters (Hg mm) measured with a sphygmomanometer.
Change from Baseline Diastolic Blood pressure at 6 months
Glycemia
Tijdsspanne: Change from Baseline Glycemia at 3 months
Fasting glycemia of each patient in milligrams per deciliter (mg/dL) measured with a glucometer.
Change from Baseline Glycemia at 3 months
Glycemia
Tijdsspanne: Change from Baseline Glycemia at 6 months
Fasting glycemia of each patient in milligrams per deciliter (mg/dL) measured with a glucometer.
Change from Baseline Glycemia at 6 months
Total cholesterol
Tijdsspanne: Change from Baseline Total cholesterol at 6 months
Total cholesterol levels of each patient in mg/dL measured in serum samples.
Change from Baseline Total cholesterol at 6 months
Triglyceride
Tijdsspanne: Change from Baseline Triglyceride at 6 months
Triglyceride levels of each patient in mg/dL measured in serum samples.
Change from Baseline Triglyceride at 6 months
LDL-cholesterol
Tijdsspanne: Change from Baseline LDL-cholesterol at 6 months
Low-density lipoprotein levels of each patient in mg/dL measured in serum samples.
Change from Baseline LDL-cholesterol at 6 months
HDL-cholesterol
Tijdsspanne: Change from Baseline HDL-cholesterol at 6 months
High-density lipoprotein cholesterol levels of each patient in mg/dL measured in serum samples.
Change from Baseline HDL-cholesterol at 6 months

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Sex
Tijdsspanne: Baseline
Sex of the patient (male/female)
Baseline
Age
Tijdsspanne: Baseline
Age of the patient at baseline examination
Baseline
Smoking
Tijdsspanne: Baseline
Smoking habit of each patient in cigarrettes per day.
Baseline

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Universidad de Granada

Medewerkers

University of Palermo

Onderzoekers

  • Hoofdonderzoeker: Francisco Mesa, PhD, Full Professor

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 november 2019

Primaire voltooiing (Werkelijk)

1 maart 2020

Studie voltooiing (Werkelijk)

1 maart 2020

Studieregistratiedata

Eerst ingediend

22 december 2020

Eerst ingediend dat voldeed aan de QC-criteria

30 december 2020

Eerst geplaatst (Werkelijk)

31 december 2020

Updates van studierecords

Laatste update geplaatst (Werkelijk)

31 december 2020

Laatste update ingediend die voldeed aan QC-criteria

30 december 2020

Laatst geverifieerd

1 december 2020

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • PON-FSE-2017-1

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren